Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide versus insulin lispro added to insulin glargine in type 2 diabetes
2020-000284-23Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tirzepatide and insulin lispro in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Mean change in HbA1c from baseline. Started Jun 2020; status: completed.
02
Drugs
tirzepatideinsulin lispro
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2020-000284-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000284-23.